S&P 500   4,596.10 (+0.64%)
DOW   34,590.69 (+0.31%)
QQQ   394.15 (+0.08%)
AAPL   168.02 (+1.65%)
MSFT   334.78 (+1.27%)
FB   315.88 (-2.64%)
GOOGL   2,872.08 (+1.20%)
AMZN   3,492.65 (-0.41%)
TSLA   1,133.79 (-0.96%)
NVDA   320.97 (-1.77%)
BABA   124.61 (-2.29%)
NIO   39.44 (+0.79%)
CGC   10.26 (-4.20%)
AMD   153.00 (-3.39%)
GE   94.94 (-0.05%)
MU   86.97 (+3.54%)
T   22.48 (-1.53%)
F   19.95 (+3.96%)
DIS   144.32 (-0.40%)
PFE   54.47 (+1.38%)
ACB   6.18 (-3.74%)
AMC   31.18 (-8.13%)
BA   192.89 (-2.51%)
S&P 500   4,596.10 (+0.64%)
DOW   34,590.69 (+0.31%)
QQQ   394.15 (+0.08%)
AAPL   168.02 (+1.65%)
MSFT   334.78 (+1.27%)
FB   315.88 (-2.64%)
GOOGL   2,872.08 (+1.20%)
AMZN   3,492.65 (-0.41%)
TSLA   1,133.79 (-0.96%)
NVDA   320.97 (-1.77%)
BABA   124.61 (-2.29%)
NIO   39.44 (+0.79%)
CGC   10.26 (-4.20%)
AMD   153.00 (-3.39%)
GE   94.94 (-0.05%)
MU   86.97 (+3.54%)
T   22.48 (-1.53%)
F   19.95 (+3.96%)
DIS   144.32 (-0.40%)
PFE   54.47 (+1.38%)
ACB   6.18 (-3.74%)
AMC   31.18 (-8.13%)
BA   192.89 (-2.51%)
S&P 500   4,596.10 (+0.64%)
DOW   34,590.69 (+0.31%)
QQQ   394.15 (+0.08%)
AAPL   168.02 (+1.65%)
MSFT   334.78 (+1.27%)
FB   315.88 (-2.64%)
GOOGL   2,872.08 (+1.20%)
AMZN   3,492.65 (-0.41%)
TSLA   1,133.79 (-0.96%)
NVDA   320.97 (-1.77%)
BABA   124.61 (-2.29%)
NIO   39.44 (+0.79%)
CGC   10.26 (-4.20%)
AMD   153.00 (-3.39%)
GE   94.94 (-0.05%)
MU   86.97 (+3.54%)
T   22.48 (-1.53%)
F   19.95 (+3.96%)
DIS   144.32 (-0.40%)
PFE   54.47 (+1.38%)
ACB   6.18 (-3.74%)
AMC   31.18 (-8.13%)
BA   192.89 (-2.51%)
S&P 500   4,596.10 (+0.64%)
DOW   34,590.69 (+0.31%)
QQQ   394.15 (+0.08%)
AAPL   168.02 (+1.65%)
MSFT   334.78 (+1.27%)
FB   315.88 (-2.64%)
GOOGL   2,872.08 (+1.20%)
AMZN   3,492.65 (-0.41%)
TSLA   1,133.79 (-0.96%)
NVDA   320.97 (-1.77%)
BABA   124.61 (-2.29%)
NIO   39.44 (+0.79%)
CGC   10.26 (-4.20%)
AMD   153.00 (-3.39%)
GE   94.94 (-0.05%)
MU   86.97 (+3.54%)
T   22.48 (-1.53%)
F   19.95 (+3.96%)
DIS   144.32 (-0.40%)
PFE   54.47 (+1.38%)
ACB   6.18 (-3.74%)
AMC   31.18 (-8.13%)
BA   192.89 (-2.51%)
NASDAQ:PHVS

Pharvaris Stock Forecast, Price & News

$14.73
+0.02 (+0.14%)
(As of 12/1/2021 01:02 PM ET)
Add
Compare
Today's Range
$14.28
$14.73
50-Day Range
$13.28
$18.55
52-Week Range
$13.14
$42.86
Volume
100 shs
Average Volume
45,051 shs
Market Capitalization
$469.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive PHVS News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter.


Pharvaris logo

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is headquartered in Leiden, the Netherlands.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PHVS
Fax
N/A
Employees
14
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$7.98 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$469.00 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
5/05/2022

MarketRank

Overall MarketRank

1.81 out of 5 stars

Medical Sector

824th out of 1,392 stocks

Pharmaceutical Preparations Industry

392nd out of 669 stocks

Analyst Opinion: 3.4Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Pharvaris (NASDAQ:PHVS) Frequently Asked Questions

Is Pharvaris a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pharvaris in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Pharvaris stock.
View analyst ratings for Pharvaris
or view top-rated stocks.

Are investors shorting Pharvaris?

Pharvaris saw a decline in short interest in November. As of November 15th, there was short interest totaling 68,400 shares, a decline of 74.8% from the October 31st total of 271,000 shares. Based on an average daily trading volume, of 27,200 shares, the days-to-cover ratio is presently 2.5 days. Currently, 0.3% of the shares of the stock are sold short.
View Pharvaris' Short Interest
.

When is Pharvaris' next earnings date?

Pharvaris is scheduled to release its next quarterly earnings announcement on Thursday, May 5th 2022.
View our earnings forecast for Pharvaris
.

How were Pharvaris' earnings last quarter?

Pharvaris (NASDAQ:PHVS) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.39) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.49) by $0.10.
View Pharvaris' earnings history
.

What price target have analysts set for PHVS?

4 brokerages have issued twelve-month price targets for Pharvaris' shares. Their forecasts range from $41.00 to $51.00. On average, they expect Pharvaris' stock price to reach $47.50 in the next year. This suggests a possible upside of 222.5% from the stock's current price.
View analysts' price targets for Pharvaris
or view top-rated stocks among Wall Street analysts.

Who are Pharvaris' key executives?

Pharvaris' management team includes the following people:
  • Mr. Berndt A. E. Modig M.B.A., MBA, CPA, Co-Founder, CEO & Exec. Director (Age 62)
  • Ms. Anna Nijdam M.Sc., R.A., Head of Fin. & Principal Accounting Officer (Age 39)
  • Dr. Jochen Knolle, Chief Scientific Officer & COO (Age 71)
  • Dr. Peng Lu M.D., Ph.D., Chief Medical Officer (Age 43)
  • Dr. Anne Lesage Ph.D., Chief Early Devel. Officer (Age 60)
  • Dr. Morgan Conn Ph.D., Chief Bus. Officer (Age 52)

When did Pharvaris IPO?

(PHVS) raised $126 million in an IPO on Friday, February 5th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers.

What is Pharvaris' stock symbol?

Pharvaris trades on the NASDAQ under the ticker symbol "PHVS."

Who are Pharvaris' major shareholders?

Pharvaris' stock is owned by many different retail and institutional investors. Top institutional investors include Deerfield Management Company L.P. Series C (5.05%), VR Adviser LLC (1.74%), Millennium Management LLC (0.50%), Goldman Sachs Group Inc. (0.09%), Morgan Stanley (0.06%) and Compagnie Lombard Odier SCmA (0.05%).

Which institutional investors are selling Pharvaris stock?

PHVS stock was sold by a variety of institutional investors in the last quarter, including VR Adviser LLC, Millennium Management LLC, and Morgan Stanley.

Which institutional investors are buying Pharvaris stock?

PHVS stock was acquired by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, Goldman Sachs Group Inc., and Compagnie Lombard Odier SCmA.

How do I buy shares of Pharvaris?

Shares of PHVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pharvaris' stock price today?

One share of PHVS stock can currently be purchased for approximately $14.73.

How much money does Pharvaris make?

Pharvaris has a market capitalization of $469.00 million.

How many employees does Pharvaris have?

Pharvaris employs 14 workers across the globe.

What is Pharvaris' official website?

The official website for Pharvaris is www.pharvaris.com.

How can I contact Pharvaris?

The company can be reached via phone at 31-71-203-6410.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.